TWO · 7754.TWO
AnnJi
NT$64.30-NT$1.40 (-2.13%)
AnnJi’s quoted price sits in the upper half of its reported 52-week range, 25.23% below the high.
Loading market information…
TWO · 6733.TWO · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 05:24 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
BioGend Therapeutics Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 49.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
BioGend Therapeutics Co., Ltd.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -NT$0.14. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow BioGend Therapeutics Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
This company specializes in the development of innovative regenerative bio-orthopedic products. Its current pipeline includes BiG-001 and BiG-006, both of which are osteoinductive bone graft substitutes. Additionally, it is advancing BiG-009, an autologous cartilage repair system. Established in 2016, the firm's operations are based in Taipei, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | -NT$0.27-68.75% vs estimate | NT$47.47M-5.06% vs estimate |
|---|
| Q4 2024 | Feb 25, 2025 | -NT$0.32-39.13% vs estimate | NT$50.58M+7.51% vs estimate |
|---|
| Q3 2024 | Nov 8, 2024 | -NT$0.25-38.89% vs estimate | NT$44.25M+10.64% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$64.30-NT$1.40 (-2.13%)
AnnJi’s quoted price sits in the upper half of its reported 52-week range, 25.23% below the high.
NT$20.10-NT$0.30 (-1.47%)
Savior Lifetec Corp.’s quoted price sits in the upper half of its reported 52-week range, 16.08% below the high.
NT$30.55-NT$0.20 (-0.65%)
Sinphar Pharmaceutical Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.86% below the high.
NT$8.37-NT$0.31 (-3.57%)
TaiGen Biopharmaceuticals Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 48.96% below the high.
NT$33.20-NT$0.60 (-1.78%)
Medigen Biotechnology Corp.’s quoted price sits in the lower half of its reported 52-week range, 23.85% below the high.
NT$68.20-NT$0.40 (-0.58%)
UnicoCell Biomed Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.82% below the high.
NT$50.00-NT$1.80 (-3.47%)
Panion & Bf Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.55% below the high.
NT$24.60-NT$0.20 (-0.81%)
Formosa Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 26.13% below the high.
